Jean‐Emmanuel Kahn

Université de Versailles Saint-Quentin-en-Yvelines

Also affiliated with CHU Ambroise Paré, Assistance Publique – Hôpitaux de Paris, Hôpital Ambroise-Paré, Hôpital Foch

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial”.

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

Journal of Allergy and Clinical Immunology(2020)10.1016/j.jaci.2020.08.037

N/A

4.7DataRank · unranked

206 citations

Jean‐Emmanuel Kahn, Marc E. Rothenberg, Andrew J. Wardlaw, Amy D. Klion, Suyong Yun Kirby +7 more

Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities

Journal of Leukocyte Biology(2024)10.1093/jleuko/qiae051

N/A

0DataRank · unranked

5 citations

Florence Roufosse, Fei Li Kuang, Steven J. Ackerman, Praveen Akuthota, Bruce S. Bochner +68 more

Mepolizumab treatment in a child with inherited TYK2 deficiency

Journal of Human Immunity(2025)10.70962/jhi.20250106

N/A

0DataRank · unranked

0 citations

Vivien Béziat, Jean-Laurent Casanova, Audrey Dupond-Athenor, Iris Fagniez, Ji Eun Han +9 more